| Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial S Saussele, J Richter, J Guilhot, FX Gruber, H Hjorth-Hansen, A Almeida, ... The Lancet Oncology 19 (6), 747-757, 2018 | 610 | 2018 |
| Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease C Fermé, H Eghbali, JH Meerwaldt, C Rieux, J Bosq, F Berger, T Girinsky, ... New England Journal of Medicine 357 (19), 1916-1927, 2007 | 575 | 2007 |
| High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial D Rossille, M Gressier, D Damotte, D Maucort-Boulch, C Pangault, ... Leukemia 28 (12), 2367-2375, 2014 | 365 | 2014 |
| Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia GL Uy, I Aldoss, MC Foster, PH Sayre, MJ Wieduwilt, AS Advani, ... Blood, The Journal of the American Society of Hematology 137 (6), 751-762, 2021 | 292 | 2021 |
| Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas A Gonzalez-Aguilar, A Idbaih, B Boisselier, N Habbita, M Rossetto, ... Clinical cancer research 18 (19), 5203-5211, 2012 | 280 | 2012 |
| Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase … C Houillier, L Taillandier, S Dureau, T Lamy, M Laadhari, O Chinot, ... Journal of clinical oncology 37 (10), 823-833, 2019 | 257 | 2019 |
| Positron emission tomography–computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset … J Trotman, M Fournier, T Lamy, JF Seymour, A Sonet, A Janikova, ... Journal of Clinical Oncology 29 (23), 3194-3200, 2011 | 236 | 2011 |
| Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of … H Ghesquieres, M Chevrier, M Laadhari, O Chinot, S Choquet, ... Annals of Oncology 30 (4), 621-628, 2019 | 225 | 2019 |
| A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy E Bachy, MJ Maurer, TM Habermann, B Gelas-Dore, D Maucort-Boulch, ... Blood, The Journal of the American Society of Hematology 132 (1), 49-58, 2018 | 218 | 2018 |
| High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized … E Gyan, C Foussard, P Bertrand, P Michenet, S Le Gouill, C Berthou, ... Blood, The Journal of the American Society of Hematology 113 (5), 995-1001, 2009 | 214 | 2009 |
| Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial G Damaj, R Gressin, K Bouabdallah, G Cartron, B Choufi, E Gyan, ... Journal of clinical oncology 31 (1), 104-110, 2013 | 210 | 2013 |
| Management and outcome of primary CNS lymphoma in the modern era: an LOC network study C Houillier, C Soussain, H Ghesquières, P Soubeyran, O Chinot, ... Neurology 94 (10), e1027-e1039, 2020 | 206 | 2020 |
| Rituximab therapy for HIV-associated Castleman disease AG Marcelin, L Aaron, C Mateus, E Gyan, I Gorin, JP Viard, V Calvez, ... Blood 102 (8), 2786-2788, 2003 | 199 | 2003 |
| Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS … A Omuro, O Chinot, L Taillandier, H Ghesquieres, C Soussain, V Delwail, ... The Lancet Haematology 2 (6), e251-e259, 2015 | 195 | 2015 |
| Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network S Langner-Lemercier, C Houillier, C Soussain, H Ghesquières, O Chinot, ... Neuro-oncology 18 (9), 1297-1303, 2016 | 193 | 2016 |
| R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma T Lamy, G Damaj, P Soubeyran, E Gyan, G Cartron, K Bouabdallah, ... Blood, The Journal of the American Society of Hematology 131 (2), 174-181, 2018 | 186 | 2018 |
| Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study GA Salles, F Morschhauser, P Solal-Céligny, C Thieblemont, T Lamy, ... Journal of clinical oncology 31 (23), 2920-2926, 2013 | 183 | 2013 |
| Etiology and outcomes of thrombotic microangiopathies G Bayer, F von Tokarski, B Thoreau, A Bauvois, C Barbet, S Cloarec, ... Clinical Journal of the American Society of Nephrology 14 (4), 557-566, 2019 | 164 | 2019 |
| Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis S Barete, O Lortholary, G Damaj, I Hirsch, MO Chandesris, C Elie, ... Blood, The Journal of the American Society of Hematology 126 (8), 1009-1016, 2015 | 158 | 2015 |
| Caspase-8 prevents sustained activation of NF-κB in monocytes undergoing macrophagic differentiation C Rébé, S Cathelin, S Launay, R Filomenko, L Prévotat, C L'Ollivier, ... Blood 109 (4), 1442-1450, 2007 | 150 | 2007 |
Gilles SallesUniversité Claude Bernard Lyon 1Zweryfikowany adres z chu-lyon.fr